BioSpace News Archive

Atlantic Healthcare plc, a specialist pharmaceutical company focused on acquiring, developing and commercializing therapeutics that address unmet patient needs and rare diseases, with a focus on gastroenterology hosted a Key Opinion Leader event on the current treatment landscape and unmet medical need in Ulcerative Colitis.

With public health officials announcing three confirmed cases of the coronavirus in Canada, there is growing concern amongst Ontarians around the spread of the virus.

Hutchison China MediTech Limited will announce its final results for the year ended December 31, 2019 on Tuesday, March 3, 2020 at 7:00 am Greenwich Mean Time.

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion for VENCLYXTO® (venetoclax) in combination with obinutuzumab for the treatment of patients with chronic lymphocytic leukemia (CLL) who were previously untreated.

IDEXX Laboratories, Inc. (NASDAQ: IDXX), reports revenues of $605 million for the fourth quarter of 2019, an increase of 10% compared to the prior year period on a reported and organic basis.

Nephros, Inc. (Nasdaq: NEPH) (“Nephros” or the “Company”), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical device and commercial markets, today announced the pricing of a firm commitment underwritten offering of 937,500 shares of common stock at a price to the public of $8.00 per share for aggregate gross proceeds of approximately $7,500,000,

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended a change to the marketing authorization for MAVIRET® (glecaprevir/pibrentasvir) to shorten once-daily treatment duration from 12 to 8 weeks in treatment-naïve,

Patented, industry leading Synapse VNA outranks competitive solutions

Vaxart, Inc. (NasdaqGS: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, announced today that it has initiated a program to develop a coronavirus vaccine candidate based on its proprietary oral vaccine platform, VAAST.

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that the European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for tucatinib, in combination with trastuzumab and capecitabine, for the treatment of adult patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received at least two prior anti-HER2 treatment regimens.